首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1508765

腎癌藥物市場：依治療方法、按藥理學、按分銷管道、按地區

Kidney Cancer Drugs Market, By Therapy: Targeted Therapy, Immunotherapy, and Chemotherapy, By Pharmacological Class: Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, and Others, By Distribution Channel, By Geography

出版日期: 2024年06月10日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

腎癌治療市場預計到2024年將達到68.9億美元，預計到2031年將達到103.1億美元，2024年至2031年的複合年成長率為5.9%。

圖 1. 2024 年腎癌治療市場佔有率（按地區分類）

藥物分析檢測是指利用科學技術和方法來判定腎癌（又稱腎細胞癌）。腎癌正成為全世界最常見的癌症之一。據估計，全球每年診斷出超過 40 萬例新病例。與腎癌相關的危險因子包括吸煙、肥胖、遺傳因素和接觸某些毒素。早期腎癌可能沒有任何症狀，但有些患者可能會出現尿血、體側疼痛或腹部腫塊。治療選擇範圍從局部疾病的部分或根治性切除術到針對晚期疾病的標靶治療和免疫治療。總體而言，由於發病率上升、患者獲得先進治療的機會增加以及強大的新藥研發等因素將繼續支持市場成長，全球腎癌治療市場預計在未來幾年將出現成長。

市場動態：

全球腎癌治療市場是由全球腎細胞癌盛行率上升所推動的。人口老化、肥胖率上升以及職場毒素暴露增加等風險因素不斷增加，導致疾病發生率上升。此外，已開發國家患者獲得優質標靶治療和免疫療法的機會的增加正在支持市場成長。同時，由於手術、放射治療和藥物治療等治療時間較長，患者越來越依賴維持治療。儘管市場存在有利的成長機會，但關鍵藥物專利到期和學名藥進入市場等因素可能會阻礙大型藥物開發商的收益來源。此外，新興市場的高定價和承受能力問題限制了進入更廣大市場的機會。然而，針對各種疾病途徑的臨床試驗中有大量的分子，具有未來市場擴張的潛力。

本研究的主要特點

該報告對全球腎癌治療市場進行了詳細分析，並以2023年為基準年，分析了預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。。
它還揭示了各個細分市場的潛在收益成長機會，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、績效和策略等參數，對全球腎癌治療藥物市場的主要企業進行概況分析。
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球腎癌治療藥物市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於全球腎癌治療藥物市場分析的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- Pfizer Inc.
- 3D Systems
- Novartis AG
- Bristol-Myers Squibb Company
- Roche Holding AG（Genentech, Inc.）
- Bayer AG
- Exelixis, Inc.
- Merck &Co., Inc.
- Eisai Co., Ltd.
- Aveo Pharmaceuticals
- AstraZeneca PLC
- Ipsen Biopharmaceuticals, Inc.
- GlaxoSmithKline plc
- Abbott Laboratories Source
- Amgen Inc.
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics

第10章分析師建議

升起和降落
綜合機會圖

第11章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI2399

The kidney cancer drugs market is estimated to be valued at USD 6.89 billion in 2024 and is expected to reach USD 10.31 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.

Figure 1. Kidney Cancer Drugs Market Share (%), By Region, 2024

Pharmaceutical analytical testing refers to the use of scientific techniques and methods to establish kidney cancer, also known as renal cell carcinoma. It is becoming one of the most common cancers globally. According to estimates, over 400,000 new cases are diagnosed worldwide each year. Risk factors associated with kidney cancer include tobacco use, obesity, hereditary factors, and exposure to certain toxins. While early-stage disease may present no symptoms, some patients may see blood in urine, flank pain, or an abdominal mass. Treatment options range from partial or radical nephrectomy for localized disease to targeted therapies or immunotherapy for advanced cases. Overall, the global kidney cancer drugs market is expected to grow significantly in the coming years as factors such as rising incidence of disease, improving patient access to advanced treatments, and robust pipeline of novel drugs continue to support the market growth.

Market Dynamics:

The global kidney cancer drugs market is driven by the rising prevalence of renal cell carcinoma worldwide. Growing risk factors, such as increasing geriatric population, rising obesity rates, and greater exposure to toxins at the workplace, are contributing to the rising disease incidence. Additionally, improving patient access to premium targeted therapies and immunotherapies in developed nations are supporting the market growth. At the same time, lengthy duration of treatment involving combinations of surgery, radiotherapy, and drug regimens is keeping patients dependent on maintenance therapies for longer duration. While the market sees lucrative growth opportunities, factors such as patent expiration of major drugs and market entry of generics could hamper the revenue stream of leading developers. Moreover, high pricing and affordability issues in developing nations restrict broader market access. Nevertheless, robust pipeline of molecules under clinical trials targeting different disease pathways offers potential for market expansion in future.

Key Features of the Study:

This report provides in-depth analysis of the global kidney cancer drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global kidney cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Pfizer Inc., Novartis AG, Bayer AG, Amgen, F. Hoffmann-La Roche Ltd, and Eisai Co. Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation-

By Therapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
By Pharmacological Class
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Cytokines
- Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Roche Holding AG (Genentech, Inc.)
- Bayer AG
- Exelixis, Inc.
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Aveo Pharmaceuticals
- AstraZeneca PLC
- Ipsen Biopharmaceuticals, Inc.
- GlaxoSmithKline plc
- Abbott Laboratories Source
- Amgen Inc.
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy
- Market Snapshot, By Pharmacological Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Kidney Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Kidney Cancer Drugs Market, By Therapy, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Kidney Cancer Drugs Market, By Pharmacological Class, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Angiogenesis Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
mTOR Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cytokines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Kidney Cancer Drugs Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- 3D Systems
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Roche Holding AG (Genentech, Inc.)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Exelixis, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Eisai Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Aveo Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AstraZeneca PLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Ipsen Biopharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GlaxoSmithKline plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Abbott Laboratories Source
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics